No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TRIB240816C7500
- 0.75
- 0.000.00%
15min DelayClose Jul 23 09:47 ET
0.00High0.00Low
0.75Open0.75Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover485.75%IV169.61%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type0.4655Delta0.1037Gamma4.08Leverage Ratio-0.0318Theta0.0004Rho1.90Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
Express News | Trinity Biotech Shares Are Trading Lower After the Company Entered Into an ATM Offering Agreement With Craig-Hallum Capital Group
Comments
$Trinity Biotech(TRIB.US$ Trinity Biotech Announces Increased Orders for TrinScreen HIV
and Raises Guidance For 2024 TrinScreen HIV Sales
DUBLIN, Ireland (May 13, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to ap...
and Raises Guidance For 2024 TrinScreen HIV Sales
DUBLIN, Ireland (May 13, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to ap...
$Trinity Biotech(TRIB.US$ Trinity Biotech Announces Strategic Collaboration With PulseAI To Enhance Continuous Glucose Monitor (CGM) Biosensor Technology
Benzinga· 4 mins ago
Benzinga· 4 mins ago
$Trinity Biotech(TRIB.US$ Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025
Moomoo 24/7· 2 mins ago
The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
Moomoo 24/7· 2 mins ago
The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
$Trinity Biotech(TRIB.US$ Announces Acquisition Of The CGM Assets Of Waveform Technologies, Inc.; Upfront Payment Of $12.5M Cash And 9M ADSs
1
$Trinity Biotech(TRIB.US$ Trinity Biotech (NASDAQ:TRIB) shares rose 25.13% to $0.54. The company's market cap stands at $20.7 million.
Read more